Sign Out
Prevention of venous thromboembolic events (VTE): elective hip or knee replacement surgery: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
Prevention of stroke and systemic embolism: non-valvular atrial fibrillation: Apixaban is indicated to reduce the risk of stroke, systemic embolism, and death in patients with non-valvular atrial fibrillation with one or more risk factors, including patients unsuitable for warfarin. Compared to warfarin, Apixaban also results in less bleeding, including intracranial hemorrhage.
Treatment of VTE: Apixaban is indicate for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE.
